Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sorrento Therapeutics Inc SRNE

Healthcare Biotechnology
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G... see more

Recent & Breaking News (GREY:SRNE)

Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial

GlobeNewswire June 19, 2019

Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY)

GlobeNewswire June 14, 2019

Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company

GlobeNewswire June 12, 2019

Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain

GlobeNewswire June 10, 2019

Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration

GlobeNewswire June 5, 2019

Sorrento Announces Cannabidiol (CBD) Global Joint Ventures and Commercial Strategic Partnerships

GlobeNewswire June 4, 2019

Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca).

GlobeNewswire May 21, 2019

Cannabis Bargains After Aphria's News Started Sell-Off-THC Therapeutics, Inc.

Press Releases April 18, 2019

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

GlobeNewswire April 15, 2019

Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration

GlobeNewswire April 10, 2019

Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program

GlobeNewswire March 26, 2019

Mid-Morning Market Update: Markets Open Lower; Hibbett Sports Beats Q4 Estimates

Benzinga.com  March 22, 2019

Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

GlobeNewswire March 22, 2019

Mid-Day Market Update: Superconductor Technologies Rises After Q4 Results; Staffing 360 Solutions Shares Slide

Benzinga.com  March 21, 2019

Mid-Afternoon Market Update: U.S. Stocks Turn Lower; Blucora Shares Spike Higher

Benzinga.com  March 19, 2019

Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

GlobeNewswire March 11, 2019

Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences

GlobeNewswire February 25, 2019

Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program

GlobeNewswire February 12, 2019

New Research: Key Drivers of Growth for Tapestry, FIS, News Corporation, Ollie's Bargain Outlet, Covanta Holding, and Sorrento Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire January 31, 2019

Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019

GlobeNewswire January 22, 2019